DR BRUCE LEVINE

Founding Director, Clinical Cell and Vaccine Production Facility

Dr. Levine is President of the International Society for Cell and Gene Therapy and serves on the Board of Directors of the Alliance for Regenerative Medicine. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer.

Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,200 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis.

Dr. Levine is co-inventor on 24 issued US patents and co-author of >160 manuscripts and book chapters with a Google Scholar citation h-index of 75. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania.

He has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Forbes, BBC, and other international media outlets. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins.